What is a concise reference guide for initiating each psychiatric long‑acting injectable antipsychotic, including management of missed injections, for medical staff who will administer the injections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Quick Reference Guide for Psychiatric Long-Acting Injectable (LAI) Antipsychotics

General Initiation Principles

Start LAI treatment as soon as possible after acute symptoms improve, and any patient requiring long-term antipsychotic treatment should be considered a candidate for LAI therapy 1. The evidence strongly supports early LAI initiation rather than waiting for demonstrated non-adherence or multiple relapses 2.

Pre-Injection Requirements

  • Establish oral tolerability first: Confirm the patient tolerates the oral formulation before switching to LAI (no specific duration consensus, but experts recommend establishing efficacy/tolerability) 3
  • Patient selection factors (in order of importance): Previous response/tolerability to antipsychotics, patient preference regarding side-effects, dosing convenience, and availability of formulation 3
  • Contraception: Some medications (e.g., cariprazine) require effective contraception in females of childbearing age 4

Medication-Specific Initiation Protocols

Aripiprazole Monohydrate (Abilify Maintena)

  • Loading: Can initiate with single injection (one-day initiation option available) 5
  • Oral supplementation: 14 days of oral aripiprazole required 6
  • Route: Intramuscular (IM) or subcutaneous (SC)
  • Frequency: Monthly (every 4 weeks)
  • Dosing window: ±7 days 6

Aripiprazole Lauroxil (Aristada)

  • Loading: One-day initiation option available 5
  • Oral supplementation: 21 days of oral aripiprazole
  • Route: IM only
  • Frequency: Monthly, 6-week, or 2-month intervals available
  • Dosing window: Similar flexibility to aripiprazole monohydrate

Paliperidone Palmitate (Invega Sustenna - Monthly)

  • Loading: Day 1: 234 mg deltoid, Day 8: 156 mg deltoid (loading regimen required)
  • Oral supplementation: None required (loading doses provide coverage)
  • Route: IM (deltoid for first 2 doses, then deltoid or gluteal)
  • Frequency: Monthly (every 4 weeks)
  • Dosing window: +14 days (can give up to 14 days late) 6

Paliperidone Palmitate (Invega Trinza - 3-Month)

  • Requirement: Must be stable on monthly paliperidone for at least 4 months first
  • Route: IM (deltoid or gluteal)
  • Frequency: Every 3 months

Risperidone LAI (Risperdal Consta)

  • Loading: Standard initiation without loading
  • Oral supplementation: 21 days of oral antipsychotic required (due to delayed release) 6
  • Route: IM (deep gluteal injection)
  • Frequency: Every 2 weeks
  • Special requirement: Refrigeration needed

Risperidone Subcutaneous (Perseris)

  • Loading: Monthly initiation
  • Oral supplementation: Minimal (subcutaneous formulation provides faster onset) 5
  • Route: SC (abdomen)
  • Frequency: Monthly

Olanzapine LAI (Zyprexa Relprevv)

  • Loading: Standard initiation
  • Oral supplementation: Consider overlap initially
  • Route: IM (deep gluteal)
  • Frequency: Every 2 or 4 weeks (dose-dependent)
  • Critical requirement: 3-hour post-injection observation mandatory (post-injection delirium/sedation syndrome risk)
  • REMS program: Restricted distribution

Management of Missed/Late Injections

Within Dosing Window

  • Administer the injection as soon as possible - no additional interventions needed 6
  • Document the delay and adjust future scheduling accordingly

Beyond Dosing Window - Aripiprazole Products (>7 days late)

  1. If <12 weeks since last injection: Give next dose immediately + restart oral supplementation for 14 days 6
  2. If >12 weeks: Restart full initiation protocol with loading and oral supplementation

Beyond Dosing Window - Paliperidone (>14 days late for monthly)

  1. If <4 months since last injection: Resume with single injection in deltoid + 21 days oral antipsychotic 6
  2. If 4-6 months: Resume with loading regimen (Day 1 and Day 8 deltoid injections)
  3. If >6 months: Restart complete initiation protocol

Beyond Dosing Window - Risperidone (>2 weeks late)

  1. If <4 weeks late: Give next injection + restart 21 days oral supplementation 6
  2. If >4 weeks: Restart full initiation with 21-day oral bridge

Critical Pitfall: Never assume the patient is covered if the dosing window is exceeded - plasma levels drop significantly and relapse risk increases exponentially 6

Injection Administration Checklist

Pre-Injection

  • ✓ Verify correct medication, dose, and patient
  • ✓ Check expiration date and storage requirements (risperidone Consta requires refrigeration)
  • ✓ Confirm injection site based on formulation (deltoid vs. gluteal vs. subcutaneous)
  • ✓ Review previous injection sites to rotate appropriately
  • ✓ Ensure reconstitution completed per manufacturer instructions (if applicable)

During Injection

  • ✓ Use appropriate needle gauge and length per product specifications 7
  • ✓ Inject slowly and steadily
  • ✓ Do not massage injection site after administration
  • ✓ Document injection site, time, and any immediate reactions

Post-Injection

  • ✓ Olanzapine LAI ONLY: Observe patient for 3 hours in facility (mandatory) 7
  • ✓ All others: Observe for 15-30 minutes for immediate adverse reactions
  • ✓ Schedule next appointment before patient leaves
  • ✓ Implement reminder system (phone call, text, family involvement) 6

Monitoring During Maintenance Phase

Define Adequate Trial Duration

  • Minimum trial period: Time to steady state + 1-2 injection cycles 3
  • For aripiprazole: ~4-5 months (4-5 injections)
  • For paliperidone monthly: ~3-4 months (3-4 injections)
  • For risperidone: ~3-4 months (6-8 injections)

Identifying Treatment Non-Response

  • Consensus: ≥1 adequate LAI trial needed to determine lack of efficacy 3
  • If significant positive symptoms persist after adequate trial at therapeutic dose, reassess diagnosis and consider clozapine 4

Common Adverse Effects Management

Drug-Induced Parkinsonism/Akathisia:

  • First-line: Reduce LAI dose (will take weeks to reach new steady state) 6
  • Bridge therapy: Short-term vitamin B6 or mirtazapine for akathisia until dose reduction takes effect 6
  • Alternative: Switch to lower-risk agent (aripiprazole-based products have lower EPS risk) 6

Metabolic Effects:

  • Monitor weight, glucose, lipids at baseline, 3 months, then annually
  • Consider metformin co-prescription with olanzapine or clozapine 4

Drug Interactions Requiring Dose Adjustment

CYP450 Inducers (Decrease LAI Levels)

  • Carbamazepine: Significantly reduces aripiprazole and risperidone levels → may cause symptom breakthrough 6
  • Action: Increase LAI dose or avoid combination; consider alternative mood stabilizer

CYP450 Inhibitors (Increase LAI Levels)

  • Fluvoxamine, fluoxetine: Increase aripiprazole/risperidone concentrations 6
  • Action: Reduce LAI dose by 25-50% when starting inhibitor

Critical Pitfall: Drug interactions with LAIs are often overlooked because dose adjustments take weeks to manifest at steady state - anticipate and adjust proactively 6

Proactive Adherence Strategies

Implement ALL of the following 6:

  1. Reminder systems: Phone calls 3-5 days before appointment + text message day before
  2. Family/caregiver involvement: Designate support person to receive appointment reminders
  3. Flexible scheduling: Offer evening/weekend injection clinics if possible
  4. Same-day rescheduling: If patient misses appointment, contact immediately and reschedule within dosing window
  5. Address barriers: Transportation, work conflicts, stigma concerns

Special Populations

First-Episode Psychosis

  • LAIs are appropriate and feasible in first-episode patients 1
  • Early LAI initiation may prevent the pattern of non-adherence → relapse → hospitalization 1
  • Engage patient in collaborative decision-making about convenience of monthly dosing vs. daily oral medication 8

Treatment-Resistant Schizophrenia

  • Consider LAI trial before declaring treatment resistance - "pseudo-resistance" from non-adherence is common 1
  • If LAI trial at adequate dose/duration fails, proceed to clozapine 4

Substance Use Comorbidity

  • LAIs remain appropriate - engage in non-judgmental discussion about substance use 6
  • Substance use may exacerbate symptoms but does not contraindicate LAI therapy
  • Monitor more closely for missed appointments

Switching Between LAIs

No strong consensus exists on optimal switching strategies 3, but general approach:

  1. Consider pharmacokinetic overlap: Start new LAI while previous LAI is still providing coverage
  2. Cross-titration timing: Base on half-life of each medication
  3. Oral supplementation: May be needed during transition depending on formulations
  4. Monitor closely: First 2-3 months after switch for efficacy and tolerability

Practical approach: If switching from monthly paliperidone to aripiprazole monohydrate, give first aripiprazole injection at the time next paliperidone dose would be due, with 14 days oral aripiprazole supplementation.

Documentation Requirements

For each injection, document:

  • Date and time of administration
  • Medication name, dose, lot number
  • Injection site and route
  • Patient tolerability
  • Next scheduled injection date
  • Any oral supplementation prescribed
  • Reminder system activated

Key Takeaway for Staff

The most common cause of LAI treatment failure is not medication inefficacy - it is missed injections and inadequate follow-up systems 6. Proactive appointment management and immediate intervention when doses are delayed are essential to preventing relapse and maintaining quality of life.

References

Related Questions

Can you provide a flow chart and algorithm for selecting and managing long‑acting injectable antipsychotic therapy, including loading doses, oral bridge requirements, injection intervals, and missed‑dose procedures?
What is a concise quick‑reference guide for psychiatric medications, including starting and maintenance doses, evidence‑based guidelines for initiating long‑acting injectable antipsychotics, and safety monitoring parameters, for adults receiving medication‑assisted treatment in an opioid treatment program?
How should a patient who is stable on oral risperidone 3 mg be switched to paliperidone long‑acting injection (Invega Sustenna)?
Can you describe the indications, side effects, risks, and initiation logistics (including loading doses and oral supplementation) for the second‑generation antipsychotic long‑acting injectables aripiprazole (Abilify Maintena), paliperidone (Invega Sustenna), and risperidone (Risperdal Consta), excluding olanzapine?
Can I initiate aripiprazole long‑acting injectable (Abilify LAI) in a patient who has overdosed on lithium and is experiencing worsening cognition?
What does TU (tuberculin units) in a Mantoux test mean?
In an otherwise healthy adult with a pacemaker who ingested 125 mg of oxycodone and 60 mg of clonazepam, how long will death occur without medical intervention?
In an elderly patient experiencing an acute‑phase reaction, what is the appropriate acetaminophen (paracetamol) dosing regimen, and should it be administered scheduled (around‑the‑clock) or as needed (prn)?
What is the recommended low‑molecular‑weight heparin (LMWH) management for acute cerebral venous thrombosis (CVT)?
When is a D-dimer test appropriate for ruling out venous thromboembolism?
How should chronic spontaneous urticaria be treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.